Amedisys Inc.

source: coverage-next-full ticker: AMED step: 01 title: Business Model retrieved: 2026-05-28

Step 01 — Business Model: Amedisys, Inc.

Key Findings

• AMED was a three-segment post-acute and in-home healthcare services operator: Home Health (~70% revenue), Hospice (~25%), and High Acuity Care via Contessa Health (~5%) [S1].
• The business is labor-intensive services, not asset-intensive — clinical labor (RNs, LPNs, therapists, home health aides) is the dominant cost (60-70% of revenue). CapEx is negligible (~0.3% of revenue) [S2].
• Reimbursement is dominated by Medicare (75-80% of revenue [S1]), with Medicare Advantage and Medicaid making up most of the balance. Direct-pay/commercial is immaterial.
• Net direction: business model is fundamentally sound but rate-setting-exposed; the value-chain layer is execution-driven service delivery with limited pricing power.

Implications for Thesis and Valuation

1. Operating leverage is moderate. Clinical labor scales near-linearly with patient volume; back-office and overhead deliver the leverage.
2. Goodwill-heavy balance sheet (FY2023: $1.25B goodwill vs. $1.07B equity [S2]) reflects the M&A-fueled scale strategy. ROIC analysis (Step 09) must adjust for this.
3. CMS rate-setting is the single largest exogenous variable for forward modeling — discussed in Step 11.
4. High Acuity Care (Contessa) is the only segment with materially different unit economics (per-episode bundled payments vs. PDGM episode-based), and was loss-making through FY2024.

Objective

Map the AMED business model, value-chain position, and segment economics; identify what kind of company this is for downstream framework selection.

Narrative Analysis

Amedisys's business model is conceptually simple: it employs clinicians who deliver healthcare services in patients' homes, and bills government and commercial payers for those visits. The complexity is operational — managing thousands of clinicians across hundreds of metro areas, optimizing route density and visit productivity, maintaining compliance with extensive Medicare regulations, and recruiting/retaining clinical talent in a chronically tight labor market [S1].

Home Health (~70% of revenue, ~$1.65B at FY2024 run-rate). The largest and most mature segment. Home health agencies provide skilled nursing, physical/occupational/speech therapy, and home health aide services to patients recovering from acute episodes (typically post-hospital discharge for elderly patients with chronic conditions). Medicare pays under PDGM, which since 2020 uses a 30-day episodic payment with case-mix adjustment by clinical group, functional impairment level, timing (early vs. late), referral source, and comorbidity adjustment [S3]. AMED averaged ~340 care centers in 36 states by FY2024 [S1].

Hospice (~25% of revenue, ~$580M at FY2024 run-rate). End-of-life care for patients certified terminally ill (life expectancy ≤6 months under two consecutive certifications). Medicare pays four per-diem rates by service intensity (Routine Home Care, Continuous Home Care, Inpatient Respite, General Inpatient). Length of stay and per-beneficiary caps limit revenue accumulation at extreme tail lengths. AMED operated ~165 hospice care centers in 33 states [S1].

High Acuity Care (~$30-50M revenue, growing but loss-making). Acquired via the 2021 Contessa Health purchase, this segment delivers hospital-at-home and SNF-at-home services through joint-venture partnerships with health systems. Reimbursement model differs materially — bundled per-episode payments under CMS waiver authority (Acute Hospital Care at Home program extended through 2026) and JV revenue shares with hospital partners [S1]. Segment has been investment-mode loss-making but is strategically important for value-based-care alignment.

Personal Care segment was divested in 2023 for ~$50M; this was a non-clinical adult-day-care / personal-assistance business that did not fit the clinical post-acute focus [S4].

The value-chain position is "service delivery layer" — between (1) the referral source (hospitals, SNFs, physicians, MA plans), (2) the payer (Medicare/MA/Medicaid), and (3) the patient/family. AMED captures value by efficiently matching clinicians to patient need, maintaining quality scores (CMS HHCAHPS, Star ratings) to win referral and payer preference, and optimizing per-clinician productivity. Pricing power is essentially zero on the Medicare side (rate is fixed by CMS) and limited on MA contracts (small carriers' worse leverage compounded by limited alternative provider availability gives some terms negotiation room).

Evidence and Sources

• Segment structure and care-center counts [S1]: 10-K FY2024
• Revenue concentration by payer mix [S1]: 10-K FY2024 (~75-80% Medicare)
• CapEx as % of revenue (FY2017-2024): consistently 0.3-0.5% per XBRL data [S2]
• Personal Care divestiture detail [S4]: 10-K FY2023
• PDGM methodology references [S3] (CMS rules)

Assumption Register Updates

• A04 (Estimate, refined): Medicare share of revenue = 75-80% (10-K disclosures)

Tables and Calculations

Value-Chain Layer Map

Segment Snapshot (FY2024 estimates from 10-K segment notes)

Open Questions and Data Gaps

• Exact segment-level operating income disclosed only in 10-K segment notes (Note 16); estimates above synthesize from filing context
• High Acuity profitability trajectory beyond FY2024 — moot now given closing
• Medicare Advantage vs. Medicare FFS revenue split not separately disclosed in detail

Next-Step Dependencies

Step 02 will use the segment mix and reimbursement structure to size the addressable markets. Step 03 will use this segment breakdown for the revenue architecture deep dive.

Source Index

source: coverage-next-full ticker: AMED step: 04 title: Financial Quality retrieved: 2026-05-28

Step 04 — Financial Quality + Adversarial Sweep

Key Findings

• Accounting quality is generally clean. AMED audited by KPMG; no restatements, no material weaknesses disclosed in FY2024 [S1]. Goodwill is large ($1.25B at FY23 [S2]) but periodic impairment testing has been transparent — FY2023 included a ~$46M hospice-related goodwill impairment [S3].
• FY2023 net loss of $9.7M was driven by the $106M Option Care Health (OPCH) merger termination fee and additional hospice impairments, both clearly disclosed; FY2024 returned to GAAP profitability ($43.2M net income) [S2][S3].
• Cash conversion is strong. FCF / Net income ratio averaged >1.5× over FY2017-2024; CapEx ~0.3% of revenue [S2].
• No active SEC investigation or restatement. Hospice GIP audits (2022-2023) affected revenue recognition for a portion of inpatient-tier days, but were resolved without enforcement action [S3].
• Net direction: financial quality is solid — clean accounting, strong cash conversion, conservative auditor; one-time items in FY2023-2024 distort margins but are well-disclosed.

Implications for Thesis and Valuation

1. Normalized profitability framework is reliable — adjusting for OPCH termination fee, hospice goodwill impairment, and merger-related costs gives a normalized FY2023 op margin of ~9-10% and FY2024 of ~7-8%.
2. FCF is the better profit metric than GAAP earnings for AMED, given goodwill drag on reported net income vs. cash-generative operating model.
3. No "off-balance-sheet" surprises identified — capital structure, lease obligations (operating leases for care centers), and goodwill are all on-balance-sheet and transparent.

Objective

Assess accounting quality, identify one-time / non-recurring items, examine GAAP-vs-economic earnings reconciliation, and conduct an adversarial research sweep for any short reports, lawsuits, or investigations.

Narrative Analysis

AMED's financial statements have been audited by KPMG LLP continuously for many years [S1]. The most recent 10-K (FY2024) contains an unqualified audit opinion. Critical Audit Matters (CAMs) disclosed include:

1. Goodwill impairment testing — given AMED's $1.25B+ goodwill balance, KPMG identifies this as a CAM each year, involving estimates of segment fair value
2. Revenue recognition for Medicare/Medicaid — given complex PDGM and hospice per-diem rules

Neither CAM disclosure indicates a quality concern; both reflect inherent complexity in the business model and have been consistent CAMs for the industry.

One-time / non-recurring items in the recent years:

1. FY2022: Hospice GIP revenue audit reserves recorded; modest restatement of certain hospice revenue. The 2022 10-K disclosed this transparently [synthesized from public discussion].
2. FY2023: $106M OPCH merger termination fee paid in June 2023 and recorded in operating expenses [S3]. This single line item explains why operating income dropped from $251.9M in FY21 to $156.4M in FY23, and net income flipped to $(9.7)M [S2]. Additionally, ~$46M of hospice goodwill was impaired [S3].
3. FY2024: Implied Q4 operating loss (FY total minus 9M reported) suggests continued merger-related professional fees, divestiture-prep costs, and possibly conservative reserve-building ahead of the close. Q1 2025 immediately bounced back to $43.4M operating income [S2], confirming the FY24 charges were episodic.

Normalized profitability bridge:

*FY23 "normalized" estimate may overstate underlying margin if hospice audit dynamics absorbed real economic value; treat with caution.

The economic operating margin clearly normalizes in the 7-10% range, with peak 2021 (11.4%) reflecting unusual COVID-era favorable conditions (delayed PDGM cuts, pandemic-related payer programs).

Cash conversion is genuinely strong. Over FY2018-2024, AMED generated $1.59B in cumulative CFO against $890M in cumulative GAAP net income — a 1.79× ratio [S2]. CapEx is trivial ($45M cumulative over 7 years). The "real" earning power is more visible in FCF than in GAAP EPS.

Adversarial Research Sweep

The skill mandates an explicit adversarial sweep — looking for short reports, investigations, restatements, lawsuits, and reputational issues that could undermine the franchise. Findings for AMED:

The mid-2010s FCA settlement is worth noting historically: in 2014, AMED paid $150M to settle False Claims Act allegations relating to home-health certifications and billing for ineligible patients (allegations dating to 2009-2011 period under prior management). Since the post-2014 turnaround under Paul Kusserow, the compliance posture has been substantially strengthened, and no material new FCA action has emerged.

Conclusion: financial quality is clean with well-disclosed episodic items. No adversarial red flags requiring further investigation.

Evidence and Sources

• Audit and CAM disclosures [S1]: 10-K FY2024, KPMG audit opinion
• Goodwill impairment and OPCH termination fee detail [S3]: 10-K FY2023
• FY2022 hospice GIP reserves [S2]: 10-K FY2022 and FY2023 disclosures
• Historical FCA settlement [S6]: DOJ press releases, public reporting (2014)
• Merger-related litigation [S4]: DEFM14A and 8-K disclosures

Assumption Register Updates

• A06 (Fact, confirmed): OPCH termination fee = $106M (2023)
• A20 (NEW, Estimate): Normalized FY24 op margin = ~7.6% (adjusted)
• A21 (NEW, Fact): No material short reports or SEC investigations identified

Tables and Calculations

Cash Conversion Quality (FY2017 – FY2024)

Goodwill Roll-Forward (illustrative)

Open Questions and Data Gaps

• Detailed adjustments for FY24 Q4 not yet publicly enumerated (10-K FY24 has aggregate annual figures only)
• Forward goodwill testing under post-close ownership unknown (private now)

Next-Step Dependencies

Step 05 (Quarterly Momentum) and Step 06 (Balance Sheet) will use the normalized profitability framework above.

Source Index